- Home
- BMEA vs ANL Comparison
BMEA vs ANL Comparison
Compare BMEA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ANL
- Stock Information
- Founded
- BMEA 2017
- ANL 2004
- Country
- BMEA United States
- ANL Cayman Islands
- Employees
- BMEA N/A
- ANL N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- BMEA Health Care
- ANL
- Exchange
- BMEA Nasdaq
- ANL Nasdaq
- Market Cap
- BMEA 65.8M
- ANL 56.0M
- IPO Year
- BMEA 2021
- ANL 2023
- Fundamental
- Price
- BMEA $1.57
- ANL $1.45
- Analyst Decision
- BMEA Strong Buy
- ANL Hold
- Analyst Count
- BMEA 10
- ANL 1
- Target Price
- BMEA $21.00
- ANL N/A
- AVG Volume (30 Days)
- BMEA 957.5K
- ANL 6.9K
- Earning Date
- BMEA 08-12-2025
- ANL 08-12-2025
- Dividend Yield
- BMEA N/A
- ANL N/A
- EPS Growth
- BMEA N/A
- ANL N/A
- EPS
- BMEA N/A
- ANL N/A
- Revenue
- BMEA N/A
- ANL N/A
- Revenue This Year
- BMEA N/A
- ANL N/A
- Revenue Next Year
- BMEA N/A
- ANL N/A
- P/E Ratio
- BMEA N/A
- ANL N/A
- Revenue Growth
- BMEA N/A
- ANL N/A
- 52 Week Low
- BMEA $1.29
- ANL $1.10
- 52 Week High
- BMEA $13.07
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- BMEA 37.40
- ANL 44.72
- Support Level
- BMEA $1.72
- ANL $1.48
- Resistance Level
- BMEA $1.75
- ANL $1.55
- Average True Range (ATR)
- BMEA 0.11
- ANL 0.04
- MACD
- BMEA -0.02
- ANL -0.00
- Stochastic Oscillator
- BMEA 9.20
- ANL 25.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.